PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS

Background: Emixustat hydrochloride (formerly ACU-4429) is a nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium-specific 65 kDa protein isomerase. This study provides clinicians with a background for understanding the pharmacokinetics and safety profile of orally administered emixustat. Methods: This randomized, double-masked, placebo-controlled Phase 1b study evaluated the pharmacokinetics, tolerability, and safety of a 14-day course of oral emixustat (5, 10, 20, 30, or 40 mg) or placebo (3:1 ratio) once daily in healthy volunteers. Results: A total of 40 subjects were enrolled (mean age, 38 years; 75% male). Emixustat (n = 30) was rapidly absorbed (median Tmax, 3.0–5 hours) and readily eliminated (mean t1/2, 4.6–7.9 hours), and mean Cmax and AUC0–24 generally increased in proportion to dose. No significant accumulation of emixustat was observed with multiple-dose administration. Ocular adverse events occurred in 67% of the subjects who received emixustat; all were considered mild and resolved after study completion. Systemic adverse events were minimal. Conclusion: Oral emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. These data support evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration.

[1]  L. Singerman,et al.  INVESTIGATION OF ORAL FENRETINIDE FOR TREATMENT OF GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[2]  D. Birch,et al.  SAFETY AND EFFECT ON ROD FUNCTION OF ACU-4429, A NOVEL SMALL-MOLECULE VISUAL CYCLE MODULATOR , 2012, Retina.

[3]  J. Martinez-Barbera,et al.  Genetic ablation of retinal pigment epithelial cells reveals the adaptive response of the epithelium and impact on photoreceptors , 2009, Proceedings of the National Academy of Sciences.

[4]  K. Palczewski,et al.  Metabolic Basis of Visual Cycle Inhibition by Retinoid and Nonretinoid Compounds in the Vertebrate Retina* , 2008, Journal of Biological Chemistry.

[5]  G. Abecasis,et al.  Inflammation in the pathogenesis of age-related macular degeneration , 2008, British Journal of Ophthalmology.

[6]  Jens Dreyhaupt,et al.  Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. , 2007, American journal of ophthalmology.

[7]  K. Palczewski,et al.  Effects of Potent Inhibitors of the Retinoid Cycle on Visual Function and Photoreceptor Protection from Light Damage in Mice , 2006, Molecular Pharmacology.

[8]  R. Radu,et al.  Characterization of Native Retinal Fluorophores Involved in Biosynthesis of A2E and Lipofuscin-associated Retinopathies* , 2006, Journal of Biological Chemistry.

[9]  Jens Dreyhaupt,et al.  Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. , 2006, Investigative ophthalmology & visual science.

[10]  D. Bok,et al.  Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. , 2005, Investigative ophthalmology & visual science.

[11]  Olaf Strauss,et al.  The retinal pigment epithelium in visual function. , 2005, Physiological reviews.

[12]  K. Palczewski,et al.  Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Dreyhaupt,et al.  Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.

[14]  M. Zarbin.  Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.

[15]  A. Bird,et al.  Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. , 2004, Investigative ophthalmology & visual science.

[16]  K. Nakanishi,et al.  A2E, a byproduct of the visual cycle , 2003, Vision Research.

[17]  P. Sieving,et al.  Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C Bellman,et al.  Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. , 2001, Investigative ophthalmology & visual science.

[19]  J. Weiter,et al.  [In vivo fundus fluorescence measurements in patients with age related macular degeneration]. , 1995, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[20]  C K Dorey,et al.  In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. , 1995, Investigative ophthalmology & visual science.

[21]  J. Weiter,et al.  Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. , 1989, Investigative ophthalmology & visual science.

[22]  J. Sparrow.  Bisretinoids of RPE lipofuscin: trigger for complement activation in age-related macular degeneration. , 2010, Advances in experimental medicine and biology.

[23]  K. Palczewski,et al.  The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. , 2010, Advances in experimental medicine and biology.